BI-1808

BI-1808 is a monoclonal antibody from BioInvent International. A first-in-class anti-TNFR2 antibody that is part of BioInvent's programme targeting tumour-associated regulatory T cells; tested alone and with pembrolizumab. Its furthest stage is phase 2, for cutaneous T-cell lymphoma, T-cell lymphoma, ovarian cancer and melanoma. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT04752826 recruiting (registry, checked 3 Nov 2026); updated phase 2a CTCL data presented at EHA 2026. Whether it works in people has not been established unless a trial below reports it.